Shubhra Singh, Zhilan Xiao, Karishma Bavisi, Jason Roszik, Brenda D Melendez, Zhiqiang Wang, Mark J Cantwell, Richard E Davis, Greg Lizee, Patrick Hwu, Sattva S Neelapu, Willem W Overwijk, Manisha Singh
{"title":"更正：IL-1α介导黑色素瘤对免疫疗法的先天和后天抵抗。","authors":"Shubhra Singh, Zhilan Xiao, Karishma Bavisi, Jason Roszik, Brenda D Melendez, Zhiqiang Wang, Mark J Cantwell, Richard E Davis, Greg Lizee, Patrick Hwu, Sattva S Neelapu, Willem W Overwijk, Manisha Singh","doi":"10.4049/jimmunol.2300689","DOIUrl":null,"url":null,"abstract":"<jats:title>Abstract</jats:title> Singh, S., Z. Xiao, K. Bavisi, J. Roszik, B. D. Melendez, Z. Wang, M. J. Cantwell, R. E. Davis, G. Lizee, P. Hwu, S. S. Neelapu, W. W. Overwijk, and M. Singh. 2021. IL-1α mediates innate and acquired resistance to immunotherapy in melanoma. J. Immunol. 206: 1966–1975. The Materials and Methods section erroneously omitted the manufacturer and clone of one of the Ab reagents used under the heading “Tumor induction, treatment, and monitoring.” The second sentence in this section reads “Three days after tumor inoculation, mice were treated with i.p. injection of 200 μg of anti–CTLA-4 (9H10), anti-mouse Ly6G (1A8), anti–IL-1α (ALF-161), anti–IL-1β (B122), anti–IL-1R1 (JAMA-147), and/or 200 μg of anti–PD-L1 (10F.9G2) (all from Bio X Cell) or their isotype control Abs.” It should have read “Three days after tumor inoculation, mice were treated with i.p. injection of 200 μg of anti–CTLA-4 (9H10, Bio X Cell), anti-mouse Ly6G (1A8, Bio X Cell), anti–IL-1α (Flo1-2a, XBiotech), anti–IL-1β (B122, Bio X Cell), anti–IL-1R1 (JAMA-147, Bio X Cell), and/or 200 μg of anti–PD-L1 (10F.9G2, Bio X Cell) or their isotype control Abs.”","PeriodicalId":22698,"journal":{"name":"The Journal of Immunology","volume":"40 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Corrections: IL-1α mediates innate and acquired resistance to immunotherapy in melanoma.\",\"authors\":\"Shubhra Singh, Zhilan Xiao, Karishma Bavisi, Jason Roszik, Brenda D Melendez, Zhiqiang Wang, Mark J Cantwell, Richard E Davis, Greg Lizee, Patrick Hwu, Sattva S Neelapu, Willem W Overwijk, Manisha Singh\",\"doi\":\"10.4049/jimmunol.2300689\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<jats:title>Abstract</jats:title> Singh, S., Z. Xiao, K. Bavisi, J. Roszik, B. D. Melendez, Z. Wang, M. J. Cantwell, R. E. Davis, G. Lizee, P. Hwu, S. S. Neelapu, W. W. Overwijk, and M. Singh. 2021. IL-1α mediates innate and acquired resistance to immunotherapy in melanoma. J. Immunol. 206: 1966–1975. The Materials and Methods section erroneously omitted the manufacturer and clone of one of the Ab reagents used under the heading “Tumor induction, treatment, and monitoring.” The second sentence in this section reads “Three days after tumor inoculation, mice were treated with i.p. injection of 200 μg of anti–CTLA-4 (9H10), anti-mouse Ly6G (1A8), anti–IL-1α (ALF-161), anti–IL-1β (B122), anti–IL-1R1 (JAMA-147), and/or 200 μg of anti–PD-L1 (10F.9G2) (all from Bio X Cell) or their isotype control Abs.” It should have read “Three days after tumor inoculation, mice were treated with i.p. injection of 200 μg of anti–CTLA-4 (9H10, Bio X Cell), anti-mouse Ly6G (1A8, Bio X Cell), anti–IL-1α (Flo1-2a, XBiotech), anti–IL-1β (B122, Bio X Cell), anti–IL-1R1 (JAMA-147, Bio X Cell), and/or 200 μg of anti–PD-L1 (10F.9G2, Bio X Cell) or their isotype control Abs.”\",\"PeriodicalId\":22698,\"journal\":{\"name\":\"The Journal of Immunology\",\"volume\":\"40 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-12-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Journal of Immunology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4049/jimmunol.2300689\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of Immunology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4049/jimmunol.2300689","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
[摘要]Singh, S.， Z. Xiao, K. Bavisi, J. Roszik, B. D. Melendez, Z. Wang, M. J. Cantwell, R. E. Davis, G. Lizee, P. Hwu, S. S. Neelapu, W. W. Overwijk, M. Singh。2021。IL-1α介导黑色素瘤免疫治疗的先天和获得性耐药。[j] .中华医学杂志，2006(6):389 - 398。材料和方法部分错误地省略了标题“肿瘤诱导、治疗和监测”下使用的一种Ab试剂的制造商和克隆。本节第二句应该是“肿瘤接种3天后，小鼠腹腔注射200 μg抗ctla -4 (9H10)，抗小鼠Ly6G (1A8)，抗il -1α (ALF-161)，抗il -1β (B122)，抗il - 1r1 (JAMA-147)，和/或200 μg抗pd - l1 (10F.9G2)(全部来自Bio X细胞)或其同型对照抗体。”应该是“肿瘤接种3天后，小鼠腹腔注射200 μg抗ctla -4 (9H10, Bio X细胞)，抗小鼠Ly6G (1A8, Bio X细胞)。Bio X Cell)、抗il -1α (Flo1-2a, XBiotech)、抗il -1β (B122, Bio X Cell)、抗il - 1r1 (JAMA-147, Bio X Cell)和/或200 μg抗pd - l1 (10F。9G2, Bio X Cell)或其同型对照抗体。
Corrections: IL-1α mediates innate and acquired resistance to immunotherapy in melanoma.
Abstract Singh, S., Z. Xiao, K. Bavisi, J. Roszik, B. D. Melendez, Z. Wang, M. J. Cantwell, R. E. Davis, G. Lizee, P. Hwu, S. S. Neelapu, W. W. Overwijk, and M. Singh. 2021. IL-1α mediates innate and acquired resistance to immunotherapy in melanoma. J. Immunol. 206: 1966–1975. The Materials and Methods section erroneously omitted the manufacturer and clone of one of the Ab reagents used under the heading “Tumor induction, treatment, and monitoring.” The second sentence in this section reads “Three days after tumor inoculation, mice were treated with i.p. injection of 200 μg of anti–CTLA-4 (9H10), anti-mouse Ly6G (1A8), anti–IL-1α (ALF-161), anti–IL-1β (B122), anti–IL-1R1 (JAMA-147), and/or 200 μg of anti–PD-L1 (10F.9G2) (all from Bio X Cell) or their isotype control Abs.” It should have read “Three days after tumor inoculation, mice were treated with i.p. injection of 200 μg of anti–CTLA-4 (9H10, Bio X Cell), anti-mouse Ly6G (1A8, Bio X Cell), anti–IL-1α (Flo1-2a, XBiotech), anti–IL-1β (B122, Bio X Cell), anti–IL-1R1 (JAMA-147, Bio X Cell), and/or 200 μg of anti–PD-L1 (10F.9G2, Bio X Cell) or their isotype control Abs.”
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
